 Spyridon Mastroyannis
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 8 | 2023 | 407 | 1.030 |
Why?
| | Uterine Neoplasms | 3 | 2021 | 73 | 0.510 |
Why?
| | Sentinel Lymph Node Biopsy | 2 | 2024 | 97 | 0.400 |
Why?
| | Sarcoma, Endometrial Stromal | 2 | 2021 | 3 | 0.380 |
Why?
| | Lymph Node Excision | 3 | 2021 | 140 | 0.370 |
Why?
| | Hydatidiform Mole | 2 | 2020 | 3 | 0.360 |
Why?
| | Gestational Trophoblastic Disease | 2 | 2020 | 6 | 0.360 |
Why?
| | Granulosa Cell Tumor | 2 | 2020 | 6 | 0.360 |
Why?
| | Hysterectomy | 3 | 2021 | 118 | 0.260 |
Why?
| | Sentinel Lymph Node | 1 | 2024 | 38 | 0.230 |
Why?
| | Endometrial Neoplasms | 1 | 2024 | 151 | 0.200 |
Why?
| | Genital Neoplasms, Female | 1 | 2022 | 73 | 0.200 |
Why?
| | Leiomyosarcoma | 1 | 2021 | 24 | 0.190 |
Why?
| | Vulvar Neoplasms | 1 | 2020 | 10 | 0.190 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2020 | 8 | 0.180 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 11 | 0.180 |
Why?
| | Vacuum Curettage | 1 | 2020 | 5 | 0.180 |
Why?
| | Organ Sparing Treatments | 1 | 2020 | 31 | 0.170 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 5 | 0.170 |
Why?
| | Neoplasm Staging | 5 | 2022 | 1177 | 0.170 |
Why?
| | CA-125 Antigen | 1 | 2019 | 13 | 0.170 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 60 | 0.160 |
Why?
| | Vaccines | 1 | 2023 | 376 | 0.160 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2018 | 14 | 0.160 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 91 | 0.160 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2018 | 39 | 0.150 |
Why?
| | Leuprolide | 1 | 2017 | 20 | 0.150 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 28 | 0.150 |
Why?
| | Female | 20 | 2024 | 60045 | 0.140 |
Why?
| | Lymph Nodes | 1 | 2018 | 422 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 577 | 0.130 |
Why?
| | Estrogens | 1 | 2017 | 316 | 0.120 |
Why?
| | Succinate Dehydrogenase | 1 | 2015 | 41 | 0.120 |
Why?
| | Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2014 | 2 | 0.120 |
Why?
| | Pheochromocytoma | 1 | 2015 | 54 | 0.120 |
Why?
| | Paraganglioma | 1 | 2015 | 47 | 0.120 |
Why?
| | Cushing Syndrome | 1 | 2014 | 10 | 0.120 |
Why?
| | Age Determination by Skeleton | 1 | 2014 | 18 | 0.120 |
Why?
| | Middle Aged | 11 | 2024 | 27063 | 0.120 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2015 | 81 | 0.120 |
Why?
| | Bone Development | 1 | 2014 | 48 | 0.110 |
Why?
| | Pituitary Neoplasms | 1 | 2015 | 157 | 0.110 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2014 | 132 | 0.110 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2014 | 148 | 0.110 |
Why?
| | Adenoma | 1 | 2015 | 187 | 0.110 |
Why?
| | Glucose Intolerance | 1 | 2014 | 137 | 0.110 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 124 | 0.110 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2012 | 9 | 0.100 |
Why?
| | Fatty Liver | 1 | 2014 | 217 | 0.100 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 53 | 0.100 |
Why?
| | Obesity | 2 | 2014 | 2529 | 0.100 |
Why?
| | Humans | 21 | 2024 | 115841 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4445 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2014 | 552 | 0.090 |
Why?
| | Chorionic Gonadotropin | 2 | 2020 | 78 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2024 | 12609 | 0.090 |
Why?
| | Prognosis | 3 | 2024 | 3341 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2022 | 334 | 0.080 |
Why?
| | Registries | 3 | 2022 | 1773 | 0.080 |
Why?
| | SEER Program | 2 | 2020 | 193 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 632 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2020 | 244 | 0.080 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1088 | 0.080 |
Why?
| | Adult | 8 | 2024 | 30782 | 0.080 |
Why?
| | Bone Density | 1 | 2012 | 431 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2019 | 1870 | 0.080 |
Why?
| | United States | 5 | 2022 | 12336 | 0.070 |
Why?
| | Aged | 6 | 2024 | 19282 | 0.070 |
Why?
| | Young Adult | 5 | 2020 | 10501 | 0.070 |
Why?
| | Survival Rate | 2 | 2021 | 1652 | 0.070 |
Why?
| | Liver | 1 | 2014 | 1693 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2024 | 6433 | 0.060 |
Why?
| | Adolescent | 6 | 2020 | 17943 | 0.060 |
Why?
| | Incidence | 2 | 2020 | 2333 | 0.060 |
Why?
| | Adoptive Transfer | 1 | 2023 | 200 | 0.050 |
Why?
| | Child | 5 | 2020 | 18546 | 0.050 |
Why?
| | Child, Preschool | 3 | 2020 | 9171 | 0.050 |
Why?
| | Dysgerminoma | 1 | 2020 | 3 | 0.040 |
Why?
| | Endodermal Sinus Tumor | 1 | 2020 | 7 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 39 | 0.040 |
Why?
| | Fertility Preservation | 1 | 2020 | 47 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 4960 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 862 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 819 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2015 | 2607 | 0.040 |
Why?
| | Pregnancy | 2 | 2020 | 5552 | 0.040 |
Why?
| | Receptors, LH | 1 | 2017 | 9 | 0.040 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2017 | 17 | 0.040 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2017 | 44 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2018 | 275 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2017 | 139 | 0.040 |
Why?
| | Survival Analysis | 1 | 2020 | 1221 | 0.040 |
Why?
| | Risk Factors | 2 | 2020 | 8714 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1754 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1205 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1148 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 733 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2015 | 134 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 378 | 0.030 |
Why?
| | Base Sequence | 1 | 2017 | 2120 | 0.030 |
Why?
| | Hospitalization | 1 | 2022 | 1758 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1643 | 0.030 |
Why?
| | Male | 5 | 2020 | 56101 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2014 | 225 | 0.030 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 245 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3004 | 0.020 |
Why?
| | Mice | 2 | 2015 | 15067 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2408 | 0.020 |
Why?
| | Infant | 1 | 2020 | 8000 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 4766 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 9164 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 6186 | 0.010 |
Why?
| | Animals | 2 | 2015 | 32113 | 0.010 |
Why?
|
|
Mastroyannis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|